Ironwood Pharmaceuticals (IRWD) Free Cash Flow (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Free Cash Flow data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 74.3% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $112.2 million (up 43.1% YoY), and the FY2025 full-year result was $127.0 million, up 22.83% from the prior year.
• Free Cash Flow eased to $5.1 million in Q1 2026, from $74.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $80.2 million in Q1 2023 to a low of -$15.1 million in Q2 2025.
• A 5-year average of $40.7 million and a median of $35.6 million in 2023 frame the typical range for Free Cash Flow.
• Peak annual rise in Free Cash Flow reached 390.18% in 2025, while the deepest fall reached 145.11% in 2025.
• Tracing IRWD's Free Cash Flow over 5 years: stood at $79.2 million in 2022, then plunged by 55.03% to $35.6 million in 2023, then slumped by 57.29% to $15.2 million in 2024, then surged by 390.18% to $74.6 million in 2025, then tumbled by 93.13% to $5.1 million in 2026.
• Business Quant data shows IRWD's Free Cash Flow at $5.1 million in Q1 2026, $74.6 million in Q4 2025, and $47.6 million in Q3 2025.